Aged, Dual Anti-Platelet Therapy, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
Conditions
Brief summary
The study is an investigator-sponsored, retrospective cohort study designed to compare efficacy and safety of ticagrelor in elderly patients undergoing percutaneous coronary intervention.
Interventions
DRUGTicagrelor
Patients were survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at the time of hospital discharge.All patients were followed for 1 year in the outpatient clinic after hospital discharge.
Sponsors
The First Affiliated Hospital of Dalian Medical University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
75 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age≥75 years old; * Treated with PCI (limited to stent implantation) ; * Survivors and treated with DAPT (aspirin \[100 mg once daily\], cilostazol, or indobufen)combined with a P2Y12 receptor antagonist \[clopidogrel (75 mg once daily) or ticagrelor (90 mg twice daily)\]) at discharge;
Exclusion criteria
* Coronary artery bypass graft (CABG) or only drug conservative treatment during hospitalization; * Concurrent use of oral anticoagulants; * Inability to tolerate long-term antiplatelet therapy, such as active bleeding and a bleeding tendency; * Acute infectious diseases; * Cognitive impairment; * Declined re-examination.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Types 2, 3, and 5 bleeding, as defined by the Bleeding Academic Research Consortium | 12 months | The primary safety endpoint |
| Combined major adverse cardiovascular and cerebrovascular events (MACCEs), including all-cause mortality, myocardial infarction, ischemic stroke, and any revascularization. | 12 months | The primary efficacy endpoint |
Secondary
| Measure | Time frame |
|---|---|
| Revascularization | 12 months |
| Ischemic stroke | 12 months |
| Incidence of BARC3 and 5 bleeding | 12 months |
| All-cause mortality | 12 months |
| Incidence of major and minor bleeding defined by the TIMI study | 12 months |
| Occurrence of any bleeding | 12 months |
| Incidence of major and minor bleeding defined by the PLATO study | 12 months |
| Myocardial infarction | 12 months |
Countries
China
Outcome results
None listed